SUNU Ventures

SUNU Ventures

SUNU Ventures was founded as a Venture Capital fund expressly concentrated on neurodegeneration, with a particular focus on ALS. Its Managing Partners, Craig Boyce and Felix von Coerper, lead an Amsterdam-based team that also includes a Chief Scientific Officer (Dr. Melanie Leitner), an MD dedicated to science and due diligence (Olivier Tak), and an investment committee advisor (Rist Brouwer). The fund structures itself around the thesis that neurodegenerative diseases can become managed conditions through drugs that preserve cognition and motor function. The firm deploys capital at the early stage, targeting start-up and venture-stage companies developing therapies for ALS and adjacent neurodegenerative disorders. Its strategy blends direct equity investments with a specialized mandate that avoids generalist biotech plays. The fund’s website cites a 10-year operating history but publishes no portfolio names, AUM, or deployment figures. Available records show no disclosed co-investors or fund structures beyond the single-entity vehicle operating under the ALS Investment Fund brand. SUNU Ventures publicly lists nine professionals across investment, science, finance, and compliance functions from its Amsterdam headquarters. There is no evidence of additional offices or parallel vehicles. No philanthropic foundation, real-asset arm, or external club membership is disclosed. Institutional partnerships and total deployment remain unpublished. A distinguishing structural feature is the fund’s disease-specific mandate: rather than diversify across broad biotech verticals, it channels all capital into a single neurodegenerative pathway. This concentration is paired with an in-house scientific team, including a CSO and a dedicated MD, which is uncommon among VC funds of comparable size and suggests a sourcing model driven by clinical and research networks rather than conventional venture deal flow.